Genaera Evizon macular degeneration SPA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Genaera plans to begin two identical pivotal trials of Evizon (squalamine) "in the very near future" following a special protocol assessment agreement with FDA, the firm says June 27. The trials will enroll patients with predominantly classic, minimally classic and occult forms of wet age-related macular degeneration. The primary endpoint will be visual acuity at one year; maintenance dosing will continue through two years. Genaera has three Phase II trials of Evizon ongoing. FDA selected the anti-angiogenic agent for its continuous marketing application Pilot 2 program earlier this year; the program provides frequent feedback and interaction with the agency during the IND phase of development (1Pharmaceutical Approvals Monthly January 2005, In Brief)...
You may also be interested in...
Squalamine selected for Pilot 2
FDA taps Genaera's anti-angiogenic squalamine for its Continuous Marketing Application Pilot 2 program, the firm announces Jan. 4. Squalamine was selected by CDER's Division of Anti-Inflammatory, Analgesic and Ophthalmic Drug Products; the program provides frequent scientific feedback and interaction during the IND phase, with each review division choosing one participant. Squalamine is being developed for "wet" age-related macular degeneration. Phase II trials are underway, with data expected in the first quarter. Genaera plans to begin Phase III in the first half of 2005, to run concurrently with its largest Phase II study...
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.